PRIMARY MYELOFIBROSIS

This study tests an experimental drug called DISC-0974 in about 150 adults with myelofibrosis or myelodysplastic syndrome who also have anemia. The goal is to see if the drug is safe and can help patients need fewer or no blood transfusions. The study is in early to mid stages an…

This early-phase study tests a new daily pill, AJ1-11095, in adults with myelofibrosis (a rare bone marrow cancer) whose disease has not responded or has returned after standard JAK2 inhibitor treatment. The main goals are to check safety, find the best dose, and see if it can re…

This study tests a drug called tasquinimod, given alone or with another drug (ruxolitinib), to see if it can help control myelofibrosis—a serious bone marrow disorder. About 33 adults with primary or related forms of myelofibrosis who have not responded to or cannot take standard…

This study tests whether adding navtemadlin to the standard drug ruxolitinib helps people with myelofibrosis who are not getting enough benefit from ruxolitinib alone. About 600 adults with myelofibrosis will first take ruxolitinib, then those with a weak response will be randoml…

This study tests whether combining two drugs, momelotinib and luspatercept, can help people with myelofibrosis who need regular blood transfusions go without transfusions for at least 12 weeks. About 68 adults with primary or secondary myelofibrosis, whether or not they have had …

This study tests whether giving a chemotherapy drug (decitabine) along with a JAK inhibitor (ruxolitinib, fedratinib, or pacritinib) before a stem cell transplant helps people with advanced myeloproliferative neoplasms (MPNs) get to transplant and have better outcomes. About 25 a…

This study tests a new automated method to select specific stem cells (CD34+) for transplant in people with blood cancers like leukemia or lymphoma. The goal is to lower the risk of graft-versus-host disease, a serious complication where donor cells attack the patient's body. Abo…

This study tests whether adding iadademstat to the standard drug ASTX727 works better than ASTX727 alone for people with advanced myeloproliferative neoplasms (MPNs), a group of rare blood cancers. About 62 adults whose disease has progressed to a more aggressive phase will be ra…

This study is for people with certain blood cancers (like essential thrombocythemia or myelofibrosis) who are already doing well on the drug bomedemstat. It aims to collect long-term safety information and see how well the drug continues to work. About 400 participants will conti…

This study tests whether adding the drug ruxolitinib to standard transplant care can prevent a serious side effect called graft-versus-host disease (GVHD) in older adults with myelofibrosis or related blood cancers. About 50 participants will receive ruxolitinib before, during, a…

This study is for people with myelofibrosis, a type of bone marrow cancer. It tests giving a JAK inhibitor drug before, during, and after a stem cell transplant from a half-matched donor. The goal is to reduce a serious side effect called graft-versus-host disease without raising…

This study is a registry that will follow 200 people in Germany with myelofibrosis and anemia. It will collect information on which treatments are used, how well they work, and how patients feel. The goal is to better understand current care and outcomes, not to test a new drug.

This study is looking at a type of immune cell called monocytes in people with certain blood cancers (myeloproliferative neoplasms). Researchers want to see if these cells have unique features that could help diagnose the disease or predict its course. About 70 participants will …